Disease Domain | Count |
---|---|
Infectious Diseases | 7 |
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Prophylactic vaccine | 3 |
Chemical drugs | 2 |
mRNA | 1 |
Genetically engineered subunit vaccine | 1 |
Target |
Mechanism ALK4 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EPRS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Mar 2026 |
Sponsor / Collaborator |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
G-15(Indian Council of Medical Research) ( GPER1 ) | Prostatic Cancer More | Preclinical |
G-1(Indian Council of Medical Research) ( GPER1 ) | Prostatic Cancer More | Preclinical |
OSP-rT2544 | Salmonella Infections More | Preclinical |
Halofuginone Hydrobromide ( Collagen x EPRS ) | Malaria More | Preclinical |
CTB-T2544 | Typhoid Fever More | Preclinical |